Suggestions
Govinda Bhisetti
Vice President and Head of Computational Chemistry at Cellarity
Professional Background
Govinda Bhisetti is an accomplished scientist in the field of computational chemistry and drug design, with a remarkable career spanning over three decades. He embarked on his academic journey earning a prestigious Ph. D. from the Indian Institute of Science (IISc) in Bangalore in 1986. Following his doctoral studies, Dr. Bhisetti joined the renowned Scripps Research Institute in La Jolla, California, as a postdoctoral fellow in 1987. During his tenure there, he significantly contributed to the emerging fields of protein-ligand interaction and drug design, utilizing cutting-edge technology including the Cray XMP supercomputer to simulate complex molecular interactions. This foundation laid the groundwork for a successful career in pharmaceutical research.
In 1990, Dr. Bhisetti joined Vertex Pharmaceuticals Inc., where he dedicated over 22 years of his career to advancing the realm of drug discovery within the Computational Sciences department. His leadership and innovative approach led to the development of groundbreaking therapies, including three FDA-approved drugs. Specifically, his efforts were instrumental in the discovery of two antiretroviral medications for AIDS: Agenerase (amprenavir) and Lexiva (fosamprenavir), as well as Incivek (Telaprevir), a treatment for Hepatitis C. Notably, Dr. Bhisetti is a co-inventor of these transformative drugs and is recognized for his contributions through 26 patents and 72 published research papers, which encompass a range of topics including review articles and book chapters.
In addition to his academic and research endeavors, Govinda Bhisetti has held several impressive positions, showcasing his leadership and expertise in computational chemistry. He served as the Vice President of Computational Chemistry at Cellarity and was the Head of Computational Chemistry at Biogen, further solidifying his influence in the pharmaceutical industry. Moreover, he has acted as a Principal Investigator at Biogen and as a Research Fellow II and Research Fellow at Vertex Pharmaceuticals and The Scripps Research Institute, respectively. His diverse experience positions him as a leading figure in the field of molecular modelling and drug design, with a keen focus on innovative therapeutic strategies.
Education and Achievements
Dr. Bhisetti's academic journey is marked by significant accomplishments, particularly during his time at esteemed institutions. He pursued his Ph. D. in Solid State and Structural Chemistry at the Indian Institute of Science (IISc), where he delved into the complexities of chemical structures and interactions at a molecular level. Following this, he achieved a Master of Science (M.Sc.) in Chemistry from the University of Hyderabad, further grounding his expertise in chemical sciences.
Throughout his career, Govinda has not only contributed to the pharmaceutical landscape through drug development but has also played a pivotal role in shaping the field of computational chemistry. His research specialization encompasses a broad range of areas, including molecular modeling, structure-based drug design, virtual screening, and ADME/Tox modeling. His expertise extends to the design of inhibitors against various targets, such as HIV protease, Hepatitis C virus (HCV) protease, HCV polymerase, and numerous others. This extensive skill set underscores his ability to tackle complex challenges within the pharmaceutical industry and establishes him as a trusted consultant and collaborator.
Achievements
Dr. Govinda Bhisetti's achievements are noteworthy, particularly his contributions to the development of notable FDA-approved drugs.
- Agenerase (amprenavir): An integral part of the treatment regimen for patients with HIV, showcasing his dedication to combating viral infections that pose significant public health challenges.
- Lexiva (fosamprenavir): Another antiretroviral medication that further demonstrates his effective application of computational chemistry in real-world therapeutic developments.
- Incivek (Telaprevir): A breakthrough in the treatment of Hepatitis C, reflecting his contributions to innovative solutions in virology and chronic disease management.
Furthermore, as a co-inventor on 26 patents, Dr. Bhisetti has exemplified the essence of innovation in drug development, establishing a legacy of intellectual property that supports ongoing research and development efforts across the pharmaceutical landscape. His prolific output of 72 published research papers also highlights his commitment to sharing knowledge and advancements within the scientific community.
In summary, Govinda Bhisetti’s extensive background in computational sciences and pharmacology, combined with his leadership in drug design, position him as a highly respected figure in the pharmaceutical industry. His dedication to scientific inquiry, innovation, and collaboration have led to exceptional contributions in the field of drug discovery, making him a vital asset to any organization involved in the development of novel therapeutics.